Literature DB >> 27854063

Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.

Lucio Boglione1,2, Simone Mornese Pinna3,4, Chiara Simona Cardellino3,4, Amedeo De Nicolò3,4, Jessica Cusato3,4, Chiara Carcieri3,4, Giuseppe Cariti3,4, Giovanni Di Perri3,4, Antonio D'Avolio3,4.   

Abstract

BACKGROUND: Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.
METHODS: We described the treatment with this drug combination in a real-life cohort of 20 cirrhotic patients with genotype 1 who failed the triple therapy.
RESULTS: 18 of them (90%) with Child-Pugh A, 11 (55%) with genotype 1a, 17 (85%) with more than 1 and 8 (40%) with more than 2 previous failed treatment; all patients had at baseline NS3 resistance-associated variants related to triple therapy failure. RBV was not administered due to anemia in previous treatments. The sustained virological response was 100%.
CONCLUSION: Treatment with SOF + DCV without RBV for 24 weeks is safe and effective in cirrhotic patients who failed triple therapy with the first generation of protease inhibitors.

Entities:  

Keywords:  Cirrhotic; Daclatasvir; HCV; Protease inhibitors; Ribavirin

Mesh:

Substances:

Year:  2016        PMID: 27854063     DOI: 10.1007/s15010-016-0962-3

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

2.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

3.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

4.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors:  Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Lancet       Date:  2013-11-05       Impact factor: 79.321

Review 5.  New therapeutic strategies in HCV: polymerase inhibitors.

Authors:  Ludmila Gerber; Tania M Welzel; Stefan Zeuzem
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

6.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

  6 in total
  3 in total

1.  Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.

Authors:  Mohamed Darwish Ahmed Abd Alla; Reham M Dawood; Hassan Abd El-Hafeth Rashed; Galal Farrag; Islam Abdelmawla Emran Ammar; Mohamed Mahmoud Abdel-Halim Mahmoud; Ghada M Salum; Ahmed Mohamed Abdulhamid Altanbouly; Mai A El Meguid; Mostafa K El Awady
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

Review 2.  The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.

Authors:  William Stokes; Carol Fenton; Fiona Clement; Matthew James; Paul Ronksley; Karen L Tang
Journal:  Can J Gastroenterol Hepatol       Date:  2017-03-06

Review 3.  Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.

Authors:  Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.